Aerosol XXXX for @entity5970 .

@entity1 @entity137 @entity1223 @entity26 @entity5970 @entity2841
Recently, @entity2841 ( @entity2841 ) auto-antibodies have been found in many @entity1 with @entity5970 ( @entity5970 ). The present study reports a retrospective case series of @entity1 who used aerosolised @entity2841 in the treatment of @entity5970 . Between 1999 and 2003, 12 @entity1 elected to receive aerosolised @entity2841 (250 microg b.i.d. every other week) in lieu of whole-lung lavage or observation. @entity1 characteristics, pulmonary function tests, arterial blood gas analysis, laboratory values and chest radiographs were extracted from the @entity1 's medical records. Of the six @entity1 tested, all had @entity2841 neutralising antibodies. Additionally, abnormalities in @entity2841 gene expression (one @entity1 ), receptor expression (two @entity1 ) and ability to upregulate adhesion molecules (one @entity1 ) were found. All @entity1 except one had a positive response (mean improvements in arterial @entity26 tension, alveolar-arterial @entity26 gradient, @entity1223 diffusing capacity of the lung and forced vital capacity were 17.1 mmHg, 18.4 mmHg, 16.6% pred and 13.5% pred, respectively). Two @entity1 made a complete recovery and were disease free 1 and 2 yrs after discontinuing treatment. Four @entity1 showed complete response to both the initial course or when treated again for recurrence after discontinuation of treatment. One @entity1 required dose escalation (500 microg b.i.d.) with complete response. @entity2841 was well tolerated without late @entity137 after median (range) follow-up of 30.5 (3-68) months. In conclusion, aerosolised @entity2841 is safe and effective in treating @entity5970 providing an alternative to whole-lung lavage or subcutaneous @entity2841 .
